The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Medically reviewed by Marla Anderson, MD Uterine cancer occurs when cells in the uterus (an organ in the pelvis of people ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

A sporty dad-of-four has revealed the shocking symptoms he dismissed before being diagnosed with an ultra-rare cancer hidden ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment ... in reducing both acute and long COVID symptoms in mice. A Cleveland Clinic-led clinical trial ...

After thinking he just had a stubborn sinus infection that wouldn't go away, Brian McNamara was told he had an ultra-rare ...

With little awareness amongst both healthcare professionals and the public, and the reality of being diagnosed, often at a ...

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Cervical cancer symptoms are often absent in the early stages and may only become apparent when the disease is more advanced. Abnormal vaginal bleeding is the most common symptom overall, often ...

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors, offering a new ...